Lbp Am Sa Sells 6,292 Shares of Stryker Corporation $SYK

Lbp Am Sa reduced its stake in Stryker Corporation (NYSE:SYK) by 2.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 233,042 shares of the medical technology company’s stock after selling 6,292 shares during the period. Stryker comprises approximately 1.1% of Lbp Am Sa’s investment portfolio, making the stock its 19th largest position. Lbp Am Sa owned 0.06% of Stryker worth $86,149,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in SYK. Brighton Jones LLC lifted its stake in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares during the last quarter. Perigon Wealth Management LLC grew its position in Stryker by 2.9% during the 2nd quarter. Perigon Wealth Management LLC now owns 4,329 shares of the medical technology company’s stock worth $1,713,000 after acquiring an additional 120 shares during the last quarter. Patton Fund Management Inc. acquired a new position in Stryker in the 2nd quarter worth about $239,000. ORG Partners LLC raised its position in Stryker by 89.1% in the second quarter. ORG Partners LLC now owns 121 shares of the medical technology company’s stock valued at $48,000 after purchasing an additional 57 shares during the last quarter. Finally, LVW Advisors LLC boosted its stake in shares of Stryker by 12.4% during the second quarter. LVW Advisors LLC now owns 1,000 shares of the medical technology company’s stock valued at $396,000 after purchasing an additional 110 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Trading Down 1.1%

SYK opened at $354.74 on Monday. The company has a fifty day moving average price of $359.77 and a two-hundred day moving average price of $372.68. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The company has a market cap of $135.66 billion, a P/E ratio of 46.62, a price-to-earnings-growth ratio of 2.28 and a beta of 0.89. The company has a current ratio of 1.85, a quick ratio of 1.13 and a debt-to-equity ratio of 0.68.

Stryker (NYSE:SYK) last issued its earnings results on Friday, October 31st. The medical technology company reported $3.19 EPS for the quarter, beating the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The company had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same period last year, the business posted $2.87 EPS. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. Analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Wednesday, December 31st will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, December 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. This is a boost from Stryker’s previous quarterly dividend of $0.84. Stryker’s payout ratio is 46.25%.

Analyst Ratings Changes

SYK has been the subject of several recent research reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Stryker in a research note on Monday, December 22nd. BTIG Research reiterated a “buy” rating and set a $410.00 price target on shares of Stryker in a report on Friday, November 14th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $435.00 price target on shares of Stryker in a research report on Friday, November 14th. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research report on Sunday, December 21st. Finally, Truist Financial dropped their price objective on Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a research note on Thursday, December 18th. Fourteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $430.00.

Insiders Place Their Bets

In other Stryker news, CAO William E. Berry, Jr. sold 1,953 shares of the company’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $365.49, for a total value of $713,801.97. Following the completion of the sale, the chief accounting officer owned 2,833 shares of the company’s stock, valued at $1,035,433.17. This represents a 40.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Preston Wendell Wells sold 165 shares of the business’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the completion of the sale, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at $2,449,200.72. This represents a 2.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 522,118 shares of company stock worth $185,381,932 in the last three months. 5.20% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.